Phaseline

Companies › SillaJen

SillaJen: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BAL0891
Dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)
TTK, PLK1Phase 1Advanced Solid TumorDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05768932BAL0891Phase 1Advanced Solid TumorOncologyDec 2026

Targets

TTK (1) PLK1 (1)

Companies with the same targets

Treadwell Therapeutics Cardiff Oncology

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.